Vertical integration doesn’t appear to lead to higher drug costs in Medicare, HHS OIG finds
However, data was limited, so it’s too early to make firm conclusions, the watchdog clarified. That didn’t stop the largest PBM lobby from jumping on the report as concrete proof that consolidation doesn’t drive up prices.